Results 231 to 240 of about 20,950 (257)

Secukinumab

Reactions Weekly, 2018
  +8 more sources

Secukinumab

Reactions Weekly, 2020
  +7 more sources

An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa

Expert Opinion on Biological Therapy
Introduction Until recently, biological therapy for hidradenitis suppurativa was limited to anti-tumor necrosis factor (TNF) blockade with adalimumab (ADA). However, not all patients respond to treatment with ADA.
D. Stergianou, T. Kanni, Christina Damoulari, E. Giamarellos‐Bourboulis   +3 more
semanticscholar   +1 more source

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

The Lancet, 2023
A. Kimball, G. Jemec, A. Alavi, Z. Reguiai, A. Gottlieb, F. Bechara, Carle Paul, E. G. Bourboulis, A. Villani, A. Schwinn, F. Ruëff, Larisha Pillay Ramaya, A. Reich, I. Lobo, Rodney D Sinclair, T. Passeron, A. Martorell, P. Mendes‐Bastos, Georgios Kokolakis, P. Bécherel, M. Wozniak, Ángel Martínez, Xiaoling Wei, L. Uhlmann, Anna Passera, D. Keefe, R. Martin, C. Field, Li Chen, M. Vandemeulebroecke, S. Ravichandran, E. Muscianisi   +31 more
semanticscholar   +1 more source

Secukinumab

Reactions Weekly, 2023
  +4 more sources

Secukinumab

Reactions Weekly, 2021
openaire   +2 more sources

Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet Rheumatology, 2023
N. Venhoff, W. Schmidt, R. Bergner, J. Rech, L. Unger, H. Tony, S. Finzel, I. Andreica, D. Kofler, S. Weiner, P. Lamprecht, H. Schulze-Koops, Christine App, E. Pournara, M. Mendelson, C. Sieder, M. Maricos, J. Thiel   +17 more
semanticscholar   +1 more source

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

Arthritis and Rheumatology, 2021
Atul Deodhar, Mrcp, Ricardo Blanco, Hideto Kameda   +2 more
exaly  

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

British Journal of Dermatology, 2021
Andrew Blauvelt, Carle F Paul
exaly  

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Annals of the Rheumatic Diseases, 2021
Xenofon Baraliakos, Laure  Gossec, Sławomir Jeka   +2 more
exaly